Embargo Policy

All research presented at the ACG Annual Scientific Meeting is strictly embargoed until 8:00 a.m. on the first day of the Annual Meeting. For 2014, this is Monday, October 20 at 8:00 a.m. EDT.


Poster P212:  Olmesartan-Associated Spruelike Enteropathy

Justin Hartke
Justin Hartke, MD

Poster Presentation: Sunday, Oct 19, 3:30 PM – 7:00 PM

Author Insight From Justin Hartke, MD, University of Virginia

What’s new here and important for clinicians?
As previously reported, in patients with unexplained spruelike enteropathy, defined as seronegative duodenal villous atrophy refractory to gluten-free diet, clinicians must consider olmesartan as a potential etiology. In addition, given rapid resolution of symptoms following discontinuation of olmesartan, clinicians should consider an alternative anti-hypertensive therapy prior to costly work-up or immunosuppressive therapy.

What do patients need to know?
Patients need to know potential side effects of olmesartan and that gastrointestinal symptoms may not occur until years after initiation of therapy.

Author Contact:

Justin Hartke, MD, University of Virginia

Read the Abstract

Related Abstracts

P808 Olmesartan-Induced Spruelike Enteropathy in the Community Setting
P1427 A Case of Severe Sprue-like Enteropathy Associated With Olmesartan
P1433 Olmesartan-Associated Sprue-Like Enteropathy
P1434 Not All Diarrhea and Villous Atrophy Is Celiac Disease: A Case Report on Olmesartan-Induced Enteropathy


Media Interview Requests:

Press room and video recording facilities will be available onsite. To arrange an interview with any ACG experts or abstract authors please contact Jacqueline Gaulin of ACG via email jgaulin@gi.org or by phone at 301-263-9000. From Sunday, October 19 – Wednesday, October 22, in ACG Press Room (Room 119A; Phone 215- 418-2358) at the Pennsylvania Convention Center in Philadelphia.